Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

This study has been completed.

First Received: September 27, 2002 Last Updated: June 27, 2008 History of Changes

Sponsor:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00046384

Purpose

The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.

Condition	Intervention	Phase
Bipolar I Disorder	Drug: aripiprazole	Phase III

Study Type:	Interventional
Study Design:	Treatment

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder

Drug Information available for: Aripiprazole

Eligibility

Criteria

Patients with acute symptoms of Bipolar Disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00046384

Locations

United States, Arizona
Local Institution
Scottsdale, Arizona, United States
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Chula Vista, California, United States
Local Institution
Pico Rivera, California, United States
Local Institution
San Diego, California, United States
Local Institution
Riverside, California, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Winter Park, Florida, United States
United States, New York
Local Institution
Staten Island, New York, United States
United States, Oklahoma
Local Institution
Oklahoma City, Oklahoma, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
United States, Virginia
Local Institution
Falls Church, Virginia, United States
United States, Washington
Local Institution
Bellevue, Washington, United States
Argentina
Local Institution
Mendoza, Argentina

Sponsors and Collaborators

Bristol-Myers Squibb

More Information

Additional Information:

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CN138-077
Study First Received:	September 27, 2002
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00046384 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Tranquilizing Agents
Pathologic Processes
Disease
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs

Central Nervous System Depressants
Aripiprazole
Antipsychotic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 27, 2009